Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:CLBS NASDAQ:HLVX NASDAQ:MGRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.20$3.02$2.07▼$4.20$103.07M0.39104,764 shs170,001 shsCLBSCaladrius Biosciences$6.37$0.38▼$1.24$26.05M0.91522,308 shs466,373 shsHLVXHilleVax$2.13-1.8%$1.95$1.34▼$2.17$108.81M0.76302,278 shs52,064 shsMGRMMonogram Orthopaedics$5.90+0.5%$2.88$1.92▼$6.02$209.49M0.59309,730 shs1.06 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences0.00%+1.91%-4.19%+16.36%-0.62%CLBSCaladrius Biosciences0.00%0.00%0.00%0.00%0.00%HLVXHilleVax-1.84%+3.90%+15.14%+29.09%+21.71%MGRMMonogram Orthopaedics+0.51%+78.79%+121.80%+125.19%+173.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences3.0272 of 5 stars3.63.00.00.02.83.30.0CLBSCaladrius BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AHLVXHilleVax2.0966 of 5 stars1.05.00.00.03.03.31.3MGRMMonogram Orthopaedics1.0577 of 5 stars1.82.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.25Buy$9.00181.25% UpsideCLBSCaladrius Biosciences 0.00N/AN/AN/AHLVXHilleVax 2.00Hold$2.00-6.10% DownsideMGRMMonogram Orthopaedics 3.50Strong Buy$5.40-8.47% DownsideCurrent Analyst Ratings BreakdownLatest CLBS, MGRM, ANIX, and HLVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K490.82N/AN/A$0.59 per share5.42CLBSCaladrius BiosciencesN/AN/AN/AN/A$1.54 per shareN/AHLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/AMGRMMonogram Orthopaedics$370K569.11N/AN/A$0.42 per share14.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.38N/A∞N/AN/A-68.17%-60.38%9/5/2025 (Estimated)CLBSCaladrius Biosciences-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/AHLVXHilleVax-$147.27M-$2.15N/AN/AN/AN/A-51.86%-41.45%8/14/2025 (Estimated)MGRMMonogram Orthopaedics-$16.33M-$0.45N/AN/AN/AN/A-115.71%-92.75%8/13/2025 (Estimated)Latest CLBS, MGRM, ANIX, and HLVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MGRMMonogram Orthopaedics-$0.11N/AN/AN/AN/AN/A6/3/2025Q2 2025ANIXAnixa Biosciences-$0.10-$0.09+$0.01-$0.09N/AN/A5/14/2025Q1 2025MGRMMonogram Orthopaedics-$0.12-$0.10+$0.02-$0.10N/AN/A5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AMGRMMonogram OrthopaedicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.898.89CLBSCaladrius BiosciencesN/A22.3322.33HLVXHilleVaxN/A25.3225.32MGRMMonogram OrthopaedicsN/A7.007.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%CLBSCaladrius Biosciences15.57%HLVXHilleVax86.42%MGRMMonogram Orthopaedics0.45%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%CLBSCaladrius Biosciences2.20%HLVXHilleVax24.90%MGRMMonogram Orthopaedics28.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.21 million24.06 millionOptionableCLBSCaladrius Biosciences2760.58 million59.25 millionOptionableHLVXHilleVax2050.14 million37.66 millionNot OptionableMGRMMonogram Orthopaedics2835.69 million25.66 millionNot OptionableCLBS, MGRM, ANIX, and HLVX HeadlinesRecent News About These CompaniesMonogram Orthopaedics Ends License Agreement with Mount SinaiJuly 14 at 6:07 PM | tipranks.comMGRM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Monogram Technologies to Zimmer BiometJuly 14 at 1:05 PM | globenewswire.comMonogram Technologies stock soars after Zimmer Biomet acquisition dealJuly 14 at 10:15 AM | in.investing.comZimmer Biomet to buy Monogram for $177M in cashJuly 14 at 10:15 AM | msn.comZimmer Biomet to expand robotic suite with Monogram acquisitionJuly 14 at 10:14 AM | massdevice.comMGRM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Monogram Technologies Inc. Is Fair to ShareholdersJuly 14 at 8:18 AM | businesswire.comZimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous SolutionsJuly 14 at 7:35 AM | globenewswire.comZimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous SolutionsJuly 14 at 7:30 AM | prnewswire.comMonogram Technologies Inc. (MGRM) - Yahoo FinanceJuly 13 at 12:13 AM | finance.yahoo.comMonogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred StockJuly 8, 2025 | accessnewswire.comAEarnings call transcript: Monogram Orthopaedics sees stock surge after Q1 2025 resultsMay 16, 2025 | investing.comMonogram Technologies Inc. (MGRM) Q1 2025 Earnings Call TranscriptMay 16, 2025 | seekingalpha.comMonogram Orthopaedics, Inc. (NASDAQ:MGRM) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comA Look Ahead: Monogram Technologies's Earnings ForecastMay 15, 2025 | benzinga.comMonogram Technologies Inc.: Monogram Technologies Reports First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deMonogram Tech Gets FDA Clearance for Total Knee Arthroplasty SystemMay 15, 2025 | marketwatch.comMonogram Technologies Reports First Quarter 2025 Financial ResultsMay 14, 2025 | globenewswire.comMonogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern TimeMay 6, 2025 | accessnewswire.comACORRECTION FROM SOURCE: Monogram Technologies Receives Regulatory Approval to Start Clinical Trials in IndiaApril 29, 2025 | accessnewswire.comAMonogram Technologies Granted Regulatory Approval to Import mBôs TKA System for Clinical Investigation in IndiaApril 29, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLBS, ANIX, MGRM, and HLVX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.20 0.00 (0.00%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$3.24 +0.03 (+1.09%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Caladrius Biosciences NASDAQ:CLBSCaladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.HilleVax NASDAQ:HLVX$2.13 -0.04 (-1.84%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.12 -0.01 (-0.70%) As of 07/15/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Monogram Orthopaedics NASDAQ:MGRM$5.90 +0.03 (+0.51%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$5.89 -0.01 (-0.24%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
